In order to begin phase III trials, a sponsor needed to complete the phase II study of its intramuscular injection therapy for patients who had diabetic foot ulcers with and without peripheral arterial disease. The plan was to randomize 133 dosed patients over an enrollment period of 26 months.
Acurian has the most experience in the industry.
We’ve worked in successful trials ranging from diabetic nephropathy to diabetic neuropathy, with diabetics taking specific medications, to diabetics who must have had a CV event.
Acurian has recruited and enrolled thousands of patients for more than 60 pharmaceutical and biotech companies representing over 4,500 research sites.